Guidelines of Onkopedia: What Is New?

Area of Science:

• Oncology
• Gastroenterology
• Clinical Guidelines

Background:

• Esophageal cancer treatment guidelines are regularly updated to reflect new evidence.
• Recent advancements include targeted therapies and immunotherapies, necessitating guideline revisions.
• The Onkopedia guideline provides updated recommendations for German, Swiss, and Austrian oncologists.

Purpose of the Study:

• To present key updates from the latest Onkopedia guideline for esophageal cancer treatment.
• To highlight significant changes in perioperative, metastatic, and targeted therapy recommendations.
• To inform clinicians about new treatment options for specific molecularly defined subgroups.

Main Methods:

• Review and synthesis of the updated German, Swiss, and Austrian Onkopedia guideline.
• Focus on recommendations for perioperative chemotherapy, targeted therapy, and immunotherapy.
• Inclusion of data from key clinical trials such as ESOPEC and KEYNOTE-859.

Main Results:

• Perioperative chemotherapy with FLOT is recommended for resectable esophageal adenocarcinoma, superior to CROSS chemoradiotherapy.
• Immune checkpoint inhibition (e.g., with FLOT) is recommended for MSI-H tumors.
• New targeted therapies include zolbetuximab for Claudin 18.2 positive GEJ tumors, and TFOX for biomarker-negative cases under specific conditions.

Conclusions:

• The updated guideline incorporates perioperative chemotherapy (FLOT) and novel targeted/immune therapies for esophageal cancer.
• Specific molecular markers (MSI-H, Claudin 18.2, PD-L1) guide treatment selection.
• New treatment options offer improved efficacy for defined patient subgroups, with careful consideration of toxicity.